Your trusted source for investing success

Tag: insulin

University of British Columbia to Perform Clinical Study on the Cardiovascular and Cognitive Health Effects of Lexaria’s TurboCBDTM.

University of British Columbia to Perform Clinical Study on the Cardiovascular and Cognitive Health Effects of Lexaria’s TurboCBDTM.

Lexaria Bioscience Corporation (CSE:LXX,OTCQB:LXRP) announces the world’s first clinical study on human volunteers of cannabidiol  (CBD) within Lexaria’s high absorption TurboCBD™ product, to evaluate its effects on both cardiovascular health and cognitive function.

The study will have a double-blind and placebo controlled cross-over design measuring effects both after a single dose,

Valeritas Presents Data Showing Greater Reductions in A1c and Insulin Dose with V-Go® Wearable Insulin Delivery Device Compared to Insulin Pen Devices in Patients with Type 2 Diabetes

Valeritas Holdings (OTCQB:VLRX) today announced data showing greater reductions in A1c and insulin dose in patients with type 2 diabetes who used V-Go® Wearable Insulin Delivery device compared to patients using insulin pen devices. The data were presented as an E-Poster at The 10th International Conference on Advanced Technologies &

PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity

PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today discussed the comparator arm for its upcoming clinical trial and provided additional clarification on its recent pre-IND meeting with the U.S. Food and Drug

PharmaCyte Biotech Retains Facet Life Sciences to Guide Pancreatic Cancer Therapy Development Lifecycle with FDA

PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, officially announced today that PharmaCyte has retained Facet Life Sciences, Inc. (Facet) to guide PharmaCyte through its pancreatic cancer therapy development lifecycle with the U.S.

Lenis® Receives Next Regulatory Certification

Eternity Healthcare Inc. (OTC:ETAH), announces first regulatory approval of its Loader for the Lenis® Needle-Free Injection system.

“CE Certification opens the door for regulatory approval in the EU as well as other countries that follow the EU.  With the most difficult components already certified, we remain confident the final two certifications

PharmaCyte Biotech Announces Pre-IND Meeting Date with FDA

PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be meeting with the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) on

Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
MannKind and BIOMM Submit Registration Dossier to Brazilian Health Regulatory Agency

URL: https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/mannkind-biomm-submit-registration-dossier-brazilian-health-regulatory-agency/